Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy

Abstract In this study, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization and microvascular alterations using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. VAM da...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andreas Stadlbauer, Max Zimmermann, Stefan Oberndorfer, Arnd Doerfler, Michael Buchfelder, Gertraud Heinz, Karl Roessler
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e5e3aed873fa4895ac7c93816fd82751
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e5e3aed873fa4895ac7c93816fd82751
record_format	dspace
spelling	oai:doaj.org-article:e5e3aed873fa4895ac7c93816fd827512021-12-02T11:41:11ZVascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy10.1038/s41598-017-09048-w2045-2322https://doaj.org/article/e5e3aed873fa4895ac7c93816fd827512017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09048-whttps://doaj.org/toc/2045-2322Abstract In this study, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization and microvascular alterations using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. VAM data were acquired in 13 patients suffering from recurrent glioblastoma prior to and 3 months after bevacizumab treatment onset using a dual contrast agent injections approach as part of routine MRI. Two patients were additionally examined after the first cycle of bevacizumab to check for early treatment response. VHLs were evaluated as biomarker maps of neovascularization activity: microvessel type indicator (MTI) and curvature (Curv) of the VHL-long-axis. Early response to bevacizumab was dominated by reduction of smaller microvasculature (around 10 µm). In the 3-month follow-up, responding tumors additionally showed a reduction in larger microvasculature (>20 µm). VAM biomarker images revealed spatially heterogeneous microvascular alterations during bevacizumab treatment. Responding, non-responding, progressive, and remote-progressive tumor areas were observed. MTI may be useful to predict responding and non-responding tumor regions, and Curv to assess severity of vasogenic edema. Analysis of VHLs in combination with VAM biomarkers may lead to a new perspective on investigating the spatial heterogeneity of neovascularization and microvascular alterations in glioblastoma during antiangiogenic therapy.Andreas StadlbauerMax ZimmermannStefan OberndorferArnd DoerflerMichael BuchfelderGertraud HeinzKarl RoesslerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andreas Stadlbauer Max Zimmermann Stefan Oberndorfer Arnd Doerfler Michael Buchfelder Gertraud Heinz Karl Roessler Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
description	Abstract In this study, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization and microvascular alterations using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. VAM data were acquired in 13 patients suffering from recurrent glioblastoma prior to and 3 months after bevacizumab treatment onset using a dual contrast agent injections approach as part of routine MRI. Two patients were additionally examined after the first cycle of bevacizumab to check for early treatment response. VHLs were evaluated as biomarker maps of neovascularization activity: microvessel type indicator (MTI) and curvature (Curv) of the VHL-long-axis. Early response to bevacizumab was dominated by reduction of smaller microvasculature (around 10 µm). In the 3-month follow-up, responding tumors additionally showed a reduction in larger microvasculature (>20 µm). VAM biomarker images revealed spatially heterogeneous microvascular alterations during bevacizumab treatment. Responding, non-responding, progressive, and remote-progressive tumor areas were observed. MTI may be useful to predict responding and non-responding tumor regions, and Curv to assess severity of vasogenic edema. Analysis of VHLs in combination with VAM biomarkers may lead to a new perspective on investigating the spatial heterogeneity of neovascularization and microvascular alterations in glioblastoma during antiangiogenic therapy.
format	article
author	Andreas Stadlbauer Max Zimmermann Stefan Oberndorfer Arnd Doerfler Michael Buchfelder Gertraud Heinz Karl Roessler
author_facet	Andreas Stadlbauer Max Zimmermann Stefan Oberndorfer Arnd Doerfler Michael Buchfelder Gertraud Heinz Karl Roessler
author_sort	Andreas Stadlbauer
title	Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
title_short	Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
title_full	Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
title_fullStr	Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
title_full_unstemmed	Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
title_sort	vascular hysteresis loops and vascular architecture mapping in patients with glioblastoma treated with antiangiogenic therapy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e5e3aed873fa4895ac7c93816fd82751
work_keys_str_mv	AT andreasstadlbauer vascularhysteresisloopsandvasculararchitecturemappinginpatientswithglioblastomatreatedwithantiangiogenictherapy AT maxzimmermann vascularhysteresisloopsandvasculararchitecturemappinginpatientswithglioblastomatreatedwithantiangiogenictherapy AT stefanoberndorfer vascularhysteresisloopsandvasculararchitecturemappinginpatientswithglioblastomatreatedwithantiangiogenictherapy AT arnddoerfler vascularhysteresisloopsandvasculararchitecturemappinginpatientswithglioblastomatreatedwithantiangiogenictherapy AT michaelbuchfelder vascularhysteresisloopsandvasculararchitecturemappinginpatientswithglioblastomatreatedwithantiangiogenictherapy AT gertraudheinz vascularhysteresisloopsandvasculararchitecturemappinginpatientswithglioblastomatreatedwithantiangiogenictherapy AT karlroessler vascularhysteresisloopsandvasculararchitecturemappinginpatientswithglioblastomatreatedwithantiangiogenictherapy
_version_	1718395492707074048

Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy

Ejemplares similares